title: The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment.
abstract: BACKGROUND
  Desvenlafaxine (administered as desvenlafaxine succinate), the major active metabolite of venlafaxine, is a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD).
  
  
  OBJECTIVE
  To assess the pharmacokinetics, safety, and tolerability of desvenlafaxine in healthy volunteers vs. those with renal impairment.
  
  
  METHODS
  A single, oral, 100 mg dose of desvenlafaxine was administered to healthy subjects (n = 8) and subjects with mild (n = 9), moderate (n = 9), or severe (n = 7) renal impairment (24-h creatinine clearance, ml/min: 50 - 80, 30 - 50, or < 30 ml/min, respectively) or end-stage renal disease (ESRD; on dialysis.
authors.affiliation: Pfizer Inc., formerly Wyeth Research, Collegeville, PA 19426, , USA. Alice.Nichols@pfizer.com
authors.forename: A I
authors.initials: AI
authors.lastname: Nichols
authors.forename: L S
authors.initials: LS
authors.lastname: Richards
authors.forename: J A
authors.initials: JA
authors.lastname: Behrle
authors.forename: J A
authors.initials: JA
authors.lastname: Posener
authors.forename: S B
authors.initials: SB
authors.lastname: McGrory
authors.forename: J
authors.initials: J
authors.lastname: Paul
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D003511:Cyclohexanols / Q000009:adverse effects / Q000493:pharmacokinetics*; D000069468:Desvenlafaxine Succinate; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D014179:Neurotransmitter Uptake Inhibitors / Q000493:pharmacokinetics*; D013237:Stereoisomerism
chemical_list: D003511:Cyclohexanols; D014179:Neurotransmitter Uptake Inhibitors; D000069468:Desvenlafaxine Succinate